Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1748* | 2021 |
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 441* | 2021 |
Uterine natural killer cells and angiogenesis in recurrent reproductive failure S Quenby, H Nik, B Innes, G Lash, M Turner, J Drury, J Bulmer Human reproduction 24 (1), 45-54, 2009 | 333 | 2009 |
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
Placental phenotypes of intrauterine growth CP Sibley, MA Turner, I Cetin, P Ayuk, CA Boyd, SW D'Souza, JD Glazier, ... Pediatric research 58 (5), 827-832, 2005 | 316 | 2005 |
Human placental explants in culture: approaches and assessments RK Miller, O Genbacev, MA Turner, JD Aplin, I Caniggia, B Huppertz Placenta 26 (6), 439-448, 2005 | 289 | 2005 |
New variant Creutzfeldt-Jakob disease: psychiatric features M Zeidler, EC Johnstone, RWK Bamber, CM Dickens, CJ Fisher, ... The Lancet 350 (9082), 908-910, 1997 | 256 | 1997 |
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 233 | 2022 |
Postnatal head growth in preterm infants: a randomized controlled parenteral nutrition study C Morgan, P McGowan, S Herwitker, AE Hart, MA Turner Pediatrics 133 (1), e120-e128, 2014 | 228 | 2014 |
Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial A Sharp, C Cornforth, R Jackson, J Harrold, MA Turner, LC Kenny, ... The Lancet Child & Adolescent Health 2 (2), 93-102, 2018 | 223 | 2018 |
Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool RM Gallagher, JJ Kirkham, JR Mason, KA Bird, PR Williamson, AJ Nunn, ... PloS one 6 (12), e28096, 2011 | 222 | 2011 |
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case? Control study of inpatients in a pediatric hospital JR Bellis, JJ Kirkham, S Thiesen, EJ Conroy, LE Bracken, HL Mannix, ... BMC medicine 11, 1-8, 2013 | 166 | 2013 |
The functional regeneration of syncytiotrophoblast in cultured explants of term placenta CM Siman, CP Sibley, CJP Jones, MA Turner, SL Greenwood American Journal of Physiology-Regulatory, Integrative and Comparative …, 2001 | 163 | 2001 |
Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence RH Richey, UU Shah, M Peak, JV Craig, JL Ford, CE Barker, AJ Nunn, ... BMC pediatrics 13, 1-8, 2013 | 149 | 2013 |
Paediatric drug development: the impact of evolving regulations MA Turner, M Catapano, S Hirschfeld, C Giaquinto Advanced drug delivery reviews 73, 2-13, 2014 | 145 | 2014 |
Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children–a prospective observational cohort study of 6,601 admissions S Thiesen, EJ Conroy, JR Bellis, LE Bracken, HL Mannix, KA Bird, ... BMC medicine 11, 1-10, 2013 | 132 | 2013 |
rhIGF-1/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial D Ley, B Hallberg, I Hansen-Pupp, C Dani, LA Ramenghi, N Marlow, ... The Journal of pediatrics 206, 56-65. e8, 2019 | 131 | 2019 |
Toxic additives in medication for preterm infants A Whittaker, AE Currie, MA Turner, DJ Field, H Mulla, HC Pandya Archives of Disease in Childhood-Fetal and Neonatal Edition 94 (4), F236-F240, 2009 | 131 | 2009 |
Chronic pulmonary insufficiency of prematurity: developing optimal endpoints for drug development R Steinhorn, JM Davis, W Göpel, A Jobe, S Abman, M Laughon, ... The journal of pediatrics 191, 15-21. e1, 2017 | 125 | 2017 |
A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant AW Tang, Z Alfirevic, MA Turner, JA Drury, R Small, S Quenby Human Reproduction 28 (7), 1743-1752, 2013 | 122 | 2013 |